《高盛认股证牛熊证》平医逆市大升 跑赢同业 留意高杠杆购20469，新上市远牛53484
正股表现：平医(1833)昨日升约1.1%，今早继续上升。早上高开约2.2%後升幅扩大，最高见113.6元。现报112.9元，升约6.8%，跑赢大市及同业。有券商指平医去年下半年收入升48%，较市场预期高。并料平医佣金和服务收入可提供额外增长潜力。该行给予「跑赢大市」评级，目标价123元。
此外，昨日升约2.1%及1.7%的药明生物(2269)及阿里健康(0241)，今早亦见下跌，现报123.1及26.55元，跌约1%及0.9%。
资金流向：观察个股轮证资金流向，可见近期资金倾向部署平医认购证，过去4个交易日皆录得资金流入，合共约820万元。另一方面，则见药明牛证於本周二录得约180万元资金流入後，昨日获资金转向沽出。而阿里健康的牛证则於本周二及本周三共录得约110万元资金流入。
产品选择：投资者如看好平医，认购证方面可留意属行使价110至130元间、2个月期以上产品中，杠杆最高之一的平医购20469。牛证方面可留意属远牛的新上市平医牛53484，与现价有约19元收回距离。
平医购20469，行使价121.93元，2021年05月05日到期，实际杠杆6.4倍，行使价110至130元间、2个月期以上产品中，杠杆最高之一
平医牛53484，收回价93.8元，行使价89.8元，换股比率100，杠杆比率4.8倍，新上市远牛
投资者如看好药明，可留意新上市的药明牛52884，与现价有约10%收回距离。投资者如看好阿里健康，可留意新上市的里康牛53480，与现价有约4.6元收回距离。
药明牛52884，收回价110元，行使价108.5元，换股比率100，杠杆比率7.9倍，新上市、相近收回价牛证中杠杆最高
里康牛53480，收回价22元，行使价21.6元，换股比率50，杠杆比率4.9倍，新上市
注: 以上数据资料来自高盛认股证牛熊证网站https://www.gswarrants.com.hk/~
重要声明:
以上资讯由第三方提供，AASTOCKS.com Limited对於任何包含於、经由、连结、下载或从任何与本网站有关服务所获得之资讯、内容或广告，不声明或保证其内容之正确性或可靠性。对於您透过本网站上之广告、资讯或要约而展示、购买或取得之任何产品、资讯资料，本公司亦不负品质保证之责任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
